Mahima Kapoor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/238239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. Journal of the Peripheral Nervous System, 2019, 24, 314-319.	3.1	46
2	Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. Journal of Neuromuscular Diseases, 2019, 6, 189-199.	2.6	43
3	Thromboembolic risk with IVIg. Neurology, 2020, 94, e635-e638.	1.1	25
4	Diagnosis of amyloid neuropathy. Practical Neurology, 2019, 19, 250-258.	1.1	17
5	IVIg-exposure and thromboembolic event risk: findings from the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 876-885.	1.9	10
6	Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2022, 29, 3347-3357.	3.3	7
7	Routine blood monitoring in maintenance immunoglobulin treatment of inflammatory neuropathy: Is it clinically relevant?. Journal of the Neurological Sciences, 2020, 408, 116527.	0.6	5
8	Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies. International Journal of Neuroscience, 2022, 132, 352-361.	1.6	5
9	Neurological implications of COVID-19: a review of the science and clinical guidance. BMJ Neurology Open, 2020, 2, e000101.	1.6	4
10	Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy. Journal of Neurology, 2021, 268, 1485-1490.	3.6	3
11	An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy. Journal of the Peripheral Nervous System, 2021, 26, 461-468.	3.1	3
12	Severe cognitive impairment in a patient with CMT2A. Journal of the Peripheral Nervous System, 2018, 23, 147-148.	3.1	2
13	Immunoglobulin dosing in inflammatory neuropathy: an induction, maintenance and cessation algorithm. Neuromuscular Disorders, 2018, 28, S20-S21.	0.6	0
14	Comparison of clinical factors that impact disease activity in patients with inflammatory neuropathies. Neuromuscular Disorders, 2018, 28, S21-S22.	0.6	0
15	086â€Clinical, investigational and treatment factors do not determine prognosis of patients with inflammatory neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A27.3-A28.	1.9	0
16	FM1-4â€Intraneural perineuriomas: radiologically classic, clinically varied. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, e21.3-e20.	1.9	0